Autopsy report · NCT05639192

Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

“Lack of patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 9 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Apogenix GmbH

Sponsor type

Industry

Conditions

COVID-19

Interventions

Asunercept; Placebo

Participants

34

Sites

39

Countries

Austria, France, Georgia, Germany, India, Italy, Poland, South Africa, Spain

Trials that died the same way

• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
  “Lack of patient population” (87% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (85% match in meaning)
• Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)
  “Lack of eligible patients” (84% match in meaning)
• POLA+BR for Relapsed or Refractory DLBCL
  “Lack of sufficient patient population” (84% match in meaning)
• Ridge Preservation Comparing Simultaneous vs. Delayed Grafting
  “Not enough patients available” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.